Market Closed - Nasdaq 04:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
4.07 USD -1.93% Intraday chart for Bioventus Inc. -10.55% -22.77%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Craig-Hallum Adjusts Price Target on Bioventus to $9 From $6, Maintains Buy Rating MT
Transcript : Bioventus Inc., Q4 2023 Earnings Call, Mar 12, 2024
Earnings Flash (BVS) BIOVENTUS Posts Q4 Revenue $135.4M MT
Earnings Flash (BVS) BIOVENTUS Reports Q4 EPS $0.07 MT
Bioventus Inc. Provides Earnings Guidance for the Year 2024 CI
Bioventus Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Bioventus Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Inflation Data -2- DJ
Bioventus Inc. Enters into an Amendment with Its Credit Agreement Lenders to Enhance Financial and Operational Flexibility CI
Bioventus Hires Robert Claypoole as Chief Executive MT
Bioventus Inc Announces Executive Changes CI
Bioventus Inc. Announces Executive Changes CI
North American Morning Briefing : Futures Pause -2- DJ
Canaccord Genuity Upgrades Bioventus to Buy From Hold, Adjusts Price Target to $7 From $3.66 MT
Bioventus Contract With Aetna to Give Medicare Advantage Plan Members Access to Durolane for Knee Osteoarthritis Pain MT
Bioventus Agrees to Nationwide Contract with Aetna? Medicare Advantage Plans for Durolane for Knee Osteoarthritis CI
Transcript : Bioventus Inc., Q3 2023 Earnings Call, Nov 07, 2023
Bioventus Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Bioventus Inc. Raises Earnings Guidance for the Twelve Months Ending December 31, 2023 CI
Earnings Flash (BVS) BIOVENTUS Posts Q3 Revenue $120.8M MT
Earnings Flash (BVS) BIOVENTUS Reports Q3 EPS $0.05 MT
Transcript : Bioventus Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 08:50 AM
Insider Buy: Bioventus MT
Insider Buy: Bioventus MT
Transcript : Bioventus Inc., Q2 2023 Earnings Call, Aug 08, 2023
Chart Bioventus Inc.
More charts
Bioventus Inc. is a medical device company. The Company is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the body’s natural healing process. Its portfolio of products is grouped into three areas. Its Pain Treatments include non-surgical pain injection therapies as well as peripheral nerve stimulation (PNS) products to help the patient get back to their normal activities. Its Surgical Solutions include bone graft substitutes (BGS) that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries, as well as a portfolio of ultrasonic products used for precise bone cutting and sculpting, soft tissue management and tissue debridement in various surgeries. Its Restorative Therapies comprise a bone stimulation system, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis or other central nervous system disorders.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
4.07 USD
Average target price
8 USD
Spread / Average Target
+96.56%
Consensus
  1. Stock Market
  2. Equities
  3. BVS Stock
  4. News Bioventus Inc.
  5. Bioventus Enters Contract to Allow Cigna's Commercial Plan Members Access to Knee Osteoarthritis Pain Treatments